期刊
BLOOD REVIEWS
卷 32, 期 5, 页码 387-399出版社
CHURCHILL LIVINGSTONE
DOI: 10.1016/j.blre.2018.03.004
关键词
Chronic lymphocytic leukemia; CLL; Ibrutinib; Idelalisib; Venetoclax; Targeted therapy
类别
Chronic lymphocytic leukemia (CLL) is the most common adult leukemia in the world. Patient with CLL are at particular risk for infections due to inherent disease-related immune dysfunction in addition to the effect of certain systemic therapies on the immune system. The advent of B-cell receptor (BCR) inhibitors such as ibrutinib and idelalisib has led to a practice change that utilizes these targeted agents in the treatment of CLL, either in place of chemoimmunotherapy (CIT) or in later line settings. In this paper, we review the pathophysiology of immune dysfunction in CLL, the spectrum of immunodeficiency with the various therapeutic agents along with prevention strategies with a focus on targeted therapies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据